Ancient genes can be served as pan-cancer diagnostic and prognostic biomarkers.
ancient genes
diagnosis
pan-cancer
progenitorness score
prognosis
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
18
02
2020
revised:
06
04
2020
accepted:
12
04
2020
pubmed:
6
5
2020
medline:
30
4
2021
entrez:
6
5
2020
Statut:
ppublish
Résumé
One important challenge for cancer is efficient biomarkers monitoring its formation and developments remain greatly limited. Although the accumulated big omics data provide great opportunities to the above purpose, the biomarkers identified by the data-driven strategy often do not work well in new datasets, which is one of the main bottlenecks limiting their utilities. Given that atavistic phenotype is generally observed in cancer cells, we have been suggested that the activity of progenitor genes in tumour could serve as an efficient cancer biomarker. For doing so, we first curated 77 progenitor genes and then proposed a quantitative score to evaluate cancer progenitorness. After applying progenitorness score to ~ 22 000 samples, 33 types of cancers from 81 datasets, this method generally performs well in the diagnosis, prognosis and therapy monitoring of cancers. This study proposed a potential pan-cancer biomarker and revealed a significant role of atavism in the formation and development of cancers.
Identifiants
pubmed: 32368859
doi: 10.1111/jcmm.15347
pmc: PMC7299709
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6908-6915Informations de copyright
© 2020 Peking University. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Cell Stem Cell. 2017 Jan 5;20(1):120-134
pubmed: 28094016
Genomics Proteomics Bioinformatics. 2018 Aug;16(4):269-275
pubmed: 30266410
Neuro Oncol. 2017 Oct 1;19(10):1327-1337
pubmed: 28575485
Cell. 2019 Oct 3;179(2):561-577.e22
pubmed: 31585088
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61
pubmed: 23180760
J Cell Mol Med. 2020 Jun;24(12):6908-6915
pubmed: 32368859
Nucleic Acids Res. 2012 Jan;40(Database issue):D901-6
pubmed: 22075992
Sci Transl Med. 2016 Dec 7;8(368):368ra172
pubmed: 27928026
Adv Clin Chem. 2015;72:107-70
pubmed: 26471082
Mol Biol Evol. 2012 Jul;29(7):1703-6
pubmed: 22319151
Chem Soc Rev. 2015 May 21;44(10):2963-97
pubmed: 25739971
Science. 1938 May 20;87(2264):462-3
pubmed: 17788528
Nature. 2010 Dec 9;468(7325):768-9
pubmed: 21150985
Nucleic Acids Res. 2014 Jan;42(Database issue):D199-205
pubmed: 24214961
Nat Chem Biol. 2016 Feb;12(2):109-16
pubmed: 26656090
Phys Biol. 2011 Feb;8(1):015001
pubmed: 21301065
Trends Mol Med. 2014 Aug;20(8):460-9
pubmed: 25027972
Pharmacogenomics. 2016 May;17(7):691-700
pubmed: 27180993
Bioessays. 2017 Aug;39(8):
pubmed: 28691339
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Lancet. 2018 Sep 22;392(10152):985
pubmed: 30264708
Nucleic Acids Res. 2017 Jan 4;45(D1):D940-D944
pubmed: 27799467
Database (Oxford). 2015 Feb 27;2015:
pubmed: 25725062
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Bioessays. 2012 Jan;34(1):72-82
pubmed: 22105565
J Clin Oncol. 2001 Jul 1;19(13):3234-43
pubmed: 11432891
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
Adv Clin Chem. 2015;71:1-23
pubmed: 26411409
Adv Exp Med Biol. 2015;867:9-26
pubmed: 26530357
Nature. 2011 May 19;473(7347):337-42
pubmed: 21593866
Bioessays. 2016 Nov;38(11):1065
pubmed: 27561389
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593